From Biogen’s AdComm Meeting Will Test FDA’s “Substantial Evidence” Flexibility:

alzheimers-disease-neurons-with-amyloid-plaques-picture-id151645089

alzheimers-disease-neurons-with-amyloid-plaques-picture-id151645089—

Image: iStock/selvanegra
https://www.istockphoto.com/portfolio/selvanegra?assettype=image&mediatype=photography&sort=best

Underwriters and Partners

Xconomy Insight

Sponsored · Video
The Importance of Early Planning for Biotechs & Engaging with a CRO for Molecule Development
A Fireside Chat with Medpace's Regulatory Affairs Director David Horton
Medpace

Sponsored · Whitepaper
Navigating Challenges & Advancing Clinical Development: A Toolkit for Emerging Biotechs
How incorporating more virtual/hybrid trials and decentralized research into clinical development can better integrate healthcare into patients’ real lives and accelerate approval of new medications.
Medpace

Sponsored · Whitepaper
Biotech & Early Engagement Considerations: What Companies Must Consider When Developing an Asset
Evaluating an asset for development, including the vision, development and continuum capabilities, and global versus local development
PRA Health Sciences

Xconomy on Demand

We offer a number of ways to subscribe for free!